Edition:
United States

Merus Labs International Inc (MSLI.OQ)

MSLI.OQ on NASDAQ Stock Exchange Capital Market

1.22USD
22 Jun 2017
Change (% chg)

-- (--)
Prev Close
$1.22
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
9,333
52-wk High
$1.34
52-wk Low
$0.72

MSLI.OQ

Chart for MSLI.OQ

About

Merus Labs International Inc. is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company's products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and... (more)

Overall

Beta: 1.56
Market Cap(Mil.): $145.45
Shares Outstanding(Mil.): 117.36
Dividend: --
Yield (%): --

Financials

  MSLI.OQ Industry Sector
P/E (TTM): -- 14.08 19.12
EPS (TTM): -0.08 -- --
ROI: -3.98 -6.75 -5.05
ROE: -6.48 -6.20 -4.29

Exclusive: Timeshare operator ILG Inc explores merger - sources

ILG Inc , a U.S. provider of vacation timeshare properties, is holding early-stage talks about merging with another company after coming under pressure from activist shareholder FrontFour Capital Group, people familiar with the matter said.

Jun 15 2017

BRIEF-Merus Labs and Norgine enter into a definitive arrangement agreement

* Merus Labs and Norgine enter into a definitive arrangement agreement

May 11 2017

BRIEF-Merus Labs reports about 15 pct rise in Q2 revenue

* Merus Labs International Inc - revenues increased to $22.6 million for q2 2017 from $19.7 million for q2 2016

May 11 2017

BRIEF-Merus Labs responds to Reuters News article

* Currently using Rothschild to provide investment banking and financial advisory services

Feb 28 2017

Exclusive: Merus Labs hires Rothschild to explore options - sources

Canadian specialty drugmaker Merus Labs International Inc has hired investment bank Rothschild & Co to explore strategic alternatives, including a potential sale of the company, people familiar with the matter said on Tuesday.

Feb 28 2017

BRIEF-Merus Labs reports fiscal Q1 2017 results

* Continues to expect sintrom related product cost savings during 2017 of about half of full annualized potential of $8 million

Feb 14 2017

BRIEF-BEUTEL, GOODMAN & CO REPORTS 14.12 PCT PASSIVE STAKE IN MERUS LABS

* REPORTS 14.12 PERCENT PASSIVE STAKE IN MERUS LABS INTERNATIONAL INC AS OF DEC 31, 2016 - SEC FILING Source text (http://bit.ly/2iWQuA0) Further company coverage:

Jan 23 2017

More From Around the Web

Earnings vs. Estimates